Synergistic Activity of Remdesivir-Nirmatrelvir Combination on a SARS-CoV-2 In Vitro Model and a Case Report.
COVID-19
SARS-CoV-2
antiviral
immunosuppressed
nirmatrelvir
remdesivir
synergy
variant
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
19 07 2023
19 07 2023
Historique:
received:
31
05
2023
revised:
10
07
2023
accepted:
17
07
2023
medline:
31
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
This study aims to investigate the activity of the remdesivir-nirmatrelvir combination against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and to report a case of Coronavirus Disease 2019 (COVID-19) cured with this combination. A Vero E6 cell-based infection assay was used to investigate the in vitro activity of the remdesivir-nirmatrelvir combination. The SARS-CoV-2 strains tested were 20A.EU1, BA.1 and BA.5. After incubation, a viability assay was performed. The supernatants were collected and used for viral titration. The Highest Single Agent (HSA) reference model was calculated. An HSA score >10 is considered synergic. Remdesivir and nirmatrelvir showed synergistic activity at 48 and 72 h, with an HSA score of 52.8 and 28.6, respectively ( Remdesivir-nirmatrelvir combination has synergic activity in vitro. This combination may have a role in immunosuppressed patients with severe COVID-19 and prolonged viral shedding.
Sections du résumé
BACKGROUND
This study aims to investigate the activity of the remdesivir-nirmatrelvir combination against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and to report a case of Coronavirus Disease 2019 (COVID-19) cured with this combination.
METHODS
A Vero E6 cell-based infection assay was used to investigate the in vitro activity of the remdesivir-nirmatrelvir combination. The SARS-CoV-2 strains tested were 20A.EU1, BA.1 and BA.5. After incubation, a viability assay was performed. The supernatants were collected and used for viral titration. The Highest Single Agent (HSA) reference model was calculated. An HSA score >10 is considered synergic.
RESULTS
Remdesivir and nirmatrelvir showed synergistic activity at 48 and 72 h, with an HSA score of 52.8 and 28.6, respectively (
CONCLUSIONS
Remdesivir-nirmatrelvir combination has synergic activity in vitro. This combination may have a role in immunosuppressed patients with severe COVID-19 and prolonged viral shedding.
Identifiants
pubmed: 37515263
pii: v15071577
doi: 10.3390/v15071577
pmc: PMC10385213
pii:
doi:
Substances chimiques
Ritonavir
O3J8G9O825
remdesivir
3QKI37EEHE
Antiviral Agents
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Nat Commun. 2022 Feb 15;13(1):719
pubmed: 35169114
Antiviral Res. 2020 Jun;178:104786
pubmed: 32251767
Clin Infect Dis. 2022 Aug 24;75(1):e630-e644
pubmed: 35179197
Nat Commun. 2022 Mar 17;13(1):1547
pubmed: 35301314
Antiviral Res. 2022 Dec;208:105430
pubmed: 36209984
Eur J Med Chem. 2023 Sep 5;257:115503
pubmed: 37229831
Clin Infect Dis. 2023 Mar 4;76(5):923-925
pubmed: 36281907
Nat Microbiol. 2021 Jan;6(1):11-18
pubmed: 33273742
Int J Mol Sci. 2023 May 16;24(10):
pubmed: 37240213
Front Med (Lausanne). 2023 Jan 09;9:1062450
pubmed: 36698815
Viruses. 2021 Mar 05;13(3):
pubmed: 33807521
Nucleic Acids Res. 2020 Jul 2;48(W1):W488-W493
pubmed: 32246720
Biomedicines. 2021 Jun 18;9(6):
pubmed: 34207313
Microorganisms. 2022 Jul 21;10(7):
pubmed: 35889194
Clin Infect Dis. 2023 Mar 4;76(5):926-929
pubmed: 36326680
Curr Opin Infect Dis. 2022 Aug 1;35(4):271-279
pubmed: 35849516
mBio. 2021 Dec 21;12(6):e0334721
pubmed: 34933447
Commun Biol. 2022 Feb 22;5(1):154
pubmed: 35194144
Cell Res. 2022 Mar;32(3):322-324
pubmed: 35058606
Viruses. 2020 Oct 18;12(10):
pubmed: 33080984
EBioMedicine. 2021 Oct;72:103595
pubmed: 34571361
Clin Infect Dis. 2023 Feb 8;76(3):e172-e178
pubmed: 35869843
J Infect. 2021 Oct;83(4):467-472
pubmed: 34320390
Blood. 2022 Jul 21;140(3):236-252
pubmed: 35544585
Clin Microbiol Infect. 2022 Feb;28(2):163-177
pubmed: 35020589
Front Immunol. 2022 Dec 06;13:1015355
pubmed: 36561747
Clin Infect Dis. 2023 Jul 26;77(2):280-286
pubmed: 36976301
Int J Infect Dis. 2023 Aug;133:53-56
pubmed: 37150351
Int J Mol Sci. 2021 Feb 04;22(4):
pubmed: 33557278
Nat Immunol. 2022 Jul;23(7):1008-1020
pubmed: 35761083
Sci Transl Med. 2022 Aug 3;14(656):eabo0718
pubmed: 35482820
Sci Adv. 2022 Dec 21;8(51):eadd7197
pubmed: 36542720
Immunity. 2022 Oct 11;55(10):1779-1798
pubmed: 36182669
Viruses. 2022 Nov 01;14(11):
pubmed: 36366527
Eur J Clin Microbiol Infect Dis. 2021 Jan;40(1):1-12
pubmed: 33037944